Hudson Bay Capital Management
VRDN icon

Hudson Bay Capital Management’s Viridian Therapeutics VRDN Stock Holding History

Hudson Bay Capital Management’s Portfolio VRDN Stock Details VRDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-151,464
Closed -$4.71M – 1617
2025
Q4 		$4.71M Sell
151,464
-23,787
-14% -$652K 0.02% 516
2025
Q3 		$3.78M Buy
175,251
+55,689
+47% +$1M 0.01% 627
2025
Q2 		$1.67M Buy
+119,562
New +$1.62M 0.01% 845
2024
Q1 		– Sell
-35,176
Closed -$766K – 889
2023
Q4 		$766K Buy
+35,176
New +$555K ﹤0.01% 539

Other funds holding VRDN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Hudson Bay Capital Management's VRDN Position: Q1 2026 in Review

Hudson Bay Capital Management sold out of Viridian Therapeutics (VRDN) in Q1 2026, closing a stake of 151,464 shares — an estimated $4.71M sold.

Hudson Bay Capital Management first reported a position in VRDN in Q4 2023 and held it in 4 quarters. The position peaked at $4.71M in Q4 2025. 225 funds tracked by Wall St. Rank hold VRDN as of Q1 2026.

  • Hudson Bay Capital Management reported no remaining Viridian Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Hudson Bay Capital Management sold 151,464 Viridian Therapeutics shares in Q1 2026, an estimated $4.71M.
  • Hudson Bay Capital Management first reported a position in Viridian Therapeutics in Q4 2023 and held it in 4 quarters.
  • Hudson Bay Capital Management's Viridian Therapeutics position peaked at $4.71M in Q4 2025.
  • 225 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q1 2026.

Based on Hudson Bay Capital Management's 13F filing for Q1 2026, filed 13 May 2026.